NEJM: Study on the effect of intensive injection of new coronary pneumonia in people of all ages

Due to the recurrence of the new crown pneumonia epidemic, Israel launched the BNT162b2 booster vaccination work on July 30, 2021.
Elderly people over 60 years old who have completed the 2 doses of vaccination at least 5 months will be the first to start the third shot
.

Preliminary reports suggest that booster can effectively reduce the aging population b.

The new crown pneumonia infection recently researchers examined the vaccination age on the third needle vaccination crowd vaccine immunization impact effect

Between July 30, 2021 and October 10, 2021, researchers extracted data from 4,696,865 people over the age of 16 from the Israeli Ministry of Health database.
Participants had received two doses of BNT162B2 at least 5 months ago
.

In a preliminary analysis, the researchers compared the differences in Covid-19 diagnosis, severe illness, and mortality among people who received booster injections (both the booster group, at least 12 days after completion of vaccination) and those who did not receive booster injections (control group)

In general, the confirmed infection rate of the enhanced group is 1/10 of the control group (5 age group range, 1/9.
0-1/17.
2), and the confirmed infection rate of the enhanced group is 1/4.
9-1/10.
8 of the enhanced early group After adjustment, the difference in the infection rate was 57.
0 to 89.
5 cases per 100,000 person-days in the preliminary analysis, and 34.
4 to 38.
3 cases in the secondary analysis
.

In the preliminary and secondary analysis, among people 60 years of age or older, the incidence of serious diseases in the boost group was 1/17.

In general, the confirmed infection rate of the enhanced group is 1/10 of the control group.

Changes in infection risk after booster vaccination in each age group Changes in infection risk after booster vaccination in each age group

Studies have found that vaccination of BNT162b2 booster shots can significantly reduce the Covid-19 diagnosis rate and severe disease rate in all age groups, especially in the middle-aged and elderly population
.

Vaccination of BNT162b2 booster shots can significantly reduce the Covid-19 diagnosis rate and severe disease rate in all age groups, especially in the middle-aged and elderly population
.

Vaccination of BNT162b2 booster shots can significantly reduce the Covid-19 diagnosis rate and severe disease rate in all age groups, especially in the middle-aged and elderly population

Original source:

Yinon M et al.

Protection against Covid-19 by BNT162b2 Booster across Age Groups.
Leave a message here